Vir Biotechnology (NASDAQ:VIR) on Friday announced 24-week post-end-of-treatment data from a mid-stage trial for tobevibart ...

May 07, 2025--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases ...

PASADENA, Calif. (AP) — PASADENA, Calif. (AP) — Xencor Inc. (XNCR) on Wednesday reported a loss of $48.4 million in its first quarter. The Pasadena, California-based company said it had a loss of 66 ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...

Xencor (XNCR) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.11 per share a year ago. These figures are adjusted ...

PASADENA, Calif. (AP) — PASADENA, Calif. (AP) — Xencor Inc. (XNCR) on Wednesday reported a loss of $48.4 million in its first quarter. The Pasadena, California-based company said it had a loss ...